Mifoglame

Sitagliptin, the active ingredient in Mifoglame, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus by enhancing insulin secretion and reducing glucagon release.

GNH USA supplies Mifoglame as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, quality assurance and regulatory support for global distribution. The company adheres to EU GMP standards and offers comprehensive logistics solutions.

Mifoglame (sitagliptin) acts on the incretin pathway to manage hyperglycaemia in type 2 diabetes. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (combined with metformin): provides additional HbA1c reduction when metformin alone is insufficient. - Type 2 diabetes mellitus (combined with insulin or sulfonylureas): helps achieve target glycaemic control while minimizing insulin dose.

Sitagliptin is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient cranial pain. - Gastrointestinal discomfort: nausea, abdominal pain or diarrhoea.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema or anaphylaxis. - Joint pain: unexplained arthralgia that may be persistent.

When prescribing sitagliptin, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes during therapy. - History of pancreatitis: avoid use due to increased risk. - Concomitant insulin or sulfonylureas: monitor for hypoglycaemia. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Sitagliptin may interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure. - Co‑administration with insulin or sulfonylureas: can cause severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce sitagliptin plasma levels. - Diuretics: may affect glucose control and require monitoring. - ACE inhibitors: may increase risk of hypotension when combined with antihypertensives.